Abbott Laboratories $ABT Shares Sold by Provident Investment Management Inc.

Posted by George Bondi on Oct 26th, 2026

Provident Investment Management Inc. reduced its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 39.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,432 shares of the healthcare product maker’s stock after selling 6,690 shares during the quarter. Provident Investment Management Inc.’s holdings in Abbott Laboratories were worth $1,031,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Compass Ion Advisors LLC boosted its holdings in shares of Abbott Laboratories by 7.0% in the third quarter. Compass Ion Advisors LLC now owns 5,106 shares of the healthcare product maker’s stock valued at $505,000 after acquiring an additional 332 shares in the last quarter. Trueblood Wealth Management LLC increased its stake in shares of Abbott Laboratories by 3.1% during the third quarter. Trueblood Wealth Management LLC now owns 4,339 shares of the healthcare product maker’s stock valued at $429,000 after acquiring an additional 131 shares during the period. Radnor Capital Management LLC raised its holdings in Abbott Laboratories by 0.8% during the third quarter. Radnor Capital Management LLC now owns 19,942 shares of the healthcare product maker’s stock worth $1,971,000 after purchasing an additional 150 shares in the last quarter. Bernardo Wealth Planning LLC raised its holdings in Abbott Laboratories by 107.3% during the third quarter. Bernardo Wealth Planning LLC now owns 5,742 shares of the healthcare product maker’s stock worth $567,000 after purchasing an additional 2,972 shares in the last quarter. Finally, Robeco Schweiz AG acquired a new stake in Abbott Laboratories in the third quarter worth approximately $1,354,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABT. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a research note on Thursday, August 13th. Piper Sandler reissued an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Weiss Ratings raised Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Citigroup cut their price objective on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a report on Thursday. Finally, BTIG Research decreased their target price on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $118.32.

Check Out Our Latest Stock Analysis on ABT

Abbott Laboratories Stock Performance

Shares of ABT opened at $103.70 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm’s 50 day moving average is $105.15 and its 200-day moving average is $98.29. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The stock has a market capitalization of $179.45 billion, a P/E ratio of 38.70, a P/E/G ratio of 1.82 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The business had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same period in the prior year, the business earned $1.30 earnings per share. The business’s quarterly revenue was up 14.5% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s payout ratio is 94.03%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.